CClinicalTrials.gg
RecruitingNCT07722390Updated Jul 29, 2026

Minimally Invasive Non Surgical Treatment Using Injectable Platelet Concentrate in Treatment of Deep Pockets.

An interventional study of Injectable PRF and MINST in Intrabony Periodontal Defects, sponsored by Cairo University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled May 2025, registered Jul 2026).
  • Started May 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Sex
All
01

Study summary

The purpose of this study is to evaluate change in pocket depth following using minimally invasive non surgical combined with injectable platelet concentrate .

02

Conditions studied

  • Intrabony Periodontal Defects

Keywords

  • intrabony defect - MINST - IPR-F
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients with periodontitis stage III-IV.
  • Presence of at least one intrabony defect with radiographic component ≥ 3mm deep and PPD≥ 6mm (not affecting a tooth with 'hopeless' prognosis).
  • Patients willing to sign informed consent and to be in the study until the 6-months follow-up.
  • Full-mouth plaque score \<30% following step 1 periodontal therapy

Exclusion criteria

Exclusion Criteria:

  • Smoker/vaper (currently or in past 5 years).
  • Contributory medical history (e.g. cardiovascular disease, diabetes, psychiatric conditions).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Intervention , MINST + IPRF

    Participants will receive minimally invasive non-surgical periodontal therapy (MINST) with adjunctive local application of injectable platelet-rich fibrin (I-PRF) into the selected periodontal intrabony defect. I-PRF will be prepared from 10 mL of autologous venous blood and injected into the cleaned defect, followed by placement of a custom-made transparent vacuum-formed stent for 15 minutes to prolong local contact. Participants will receive standard oral hygiene instructions and periodontal follow-up.

    Biological: Injectable PRF

  • Active comparator
    Control , MINST only

    Participants will receive minimally invasive non-surgical periodontal therapy (MINST) alone for the selected periodontal intrabony defect, without adjunctive I-PRF or other biomaterials. Participants will receive standard oral hygiene instructions and periodontal follow-up.

    Procedure: MINST

Interventions

  • BiologicalInjectable PRF

    I-PRF will be prepared from 10 mL of autologous venous blood and injected into the cleaned defect, followed by placement of a custom-made transparent vacuum-formed stent for 15 minutes to prolong local contact

  • ProcedureMINST

    Participants will receive minimally invasive non-surgical periodontal therapy (MINST) alone using P3 Woodpecker piezoelectric scaler for the selected periodontal intrabony defect

06

What researchers measure

Primary outcomes

  1. Change in pocket depth

    Baseline measurements will be taken at the first visit. Probing depth will be measured at six sites per tooth (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, distolingual) using a UNC-15 periodontal probe

    Time frame: 6 months

Secondary outcomes

  1. Pocket closure

    Pocket depth of less than or equal 4 millimeters with no bleeding on probing at 6-month follow-up. PD will be measured from the gingival margin to the base of the pocket at six sites per tooth using a UNC-15 periodontal probe. PD reduction will be calculated by subtracting the 6-month PD from baseline PD

    Time frame: 6 months from baseline

  2. Clinical attachment gain

    CAL will be measured from the cementoenamel junction (CEJ) to the base of the pocket at the same six sites using a UNC-15 periodontal probe. CAL gain will be calculated by subtracting follow-up CAL (6 months) from baseline CAL

    Time frame: 6 months from baseline

  3. Radiographic defect reduction:

    Periapical radiographs of selected study sites will be taken at baseline and at 6 months using the parallel technique with Rinn holders. Each participating practice used the same setting and exposure time for radiographs taken at both visits to standardize positioning and minimize distortion of sequential radiographs

    Time frame: 6 months

  4. Patient reported outcomes

    To evaluate patient perceptions about the performed procedure and post-therapy period. The extent of discomfort and/or pain experienced will be evaluated using a horizontal visual analog scale (VAS) measured from scale from 1 to 10 where 1 is the lowest \& 10 is the highest.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Nibali L, Koidou V, Salomone S, Hamborg T, Allaker R, Ezra R, Zou L, Tsakos G, Gkranias N, Donos N. Minimally invasive non-surgical vs. surgical approach for periodontal intrabony defects: a randomised controlled trial. Trials. 2019 Jul 27;20(1):461. doi: 10.1186/s13063-019-3544-8. PubMed 31351492 ↗
  • Nibali L. Intrabony defects and non-surgical treatment. Prim Dent J. 2014 Aug;3(3):48-50. doi: 10.1308/205016814812736682. PubMed 25198639 ↗
  • Mehta J, Montevecchi M, Garcia-Sanchez R, Onabolu O, Linares A, Eriksson F, Ghezzi C, Donghi C, Lu EM, Nibali L. Minimally invasive non-surgical periodontal therapy of intrabony defects: A prospective multi-centre cohort study. J Clin Periodontol. 2024 Jul;51(7):905-914. doi: 10.1111/jcpe.13984. Epub 2024 May 6. PubMed 38710583 ↗
  • Iorio-Siciliano V, Blasi A, Mauriello L, Salvi GE, Ramaglia L, Sculean A. Non-Surgical Treatment of Moderate Periodontal Intrabony Defects With Adjunctive Cross-Linked Hyaluronic Acid: A Single-Blinded Randomized Controlled Clinical Trial. J Clin Periodontol. 2025 Feb;52(2):310-322. doi: 10.1111/jcpe.14078. Epub 2024 Oct 14. PubMed 39402910 ↗
  • Alshoiby MM, Fawzy El-Sayed KM, Elbattawy W, Hosny MM. Injectable platelet-rich fibrin with demineralized freeze-dried bone allograft compared to demineralized freeze-dried bone allograft in intrabony defects of patients with stage-III periodontitis: a randomized controlled clinical trial. Clin Oral Investig. 2023 Jul;27(7):3457-3467. doi: 10.1007/s00784-023-04954-y. Epub 2023 Mar 31. PubMed 37002441 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07722390
Lead sponsor
Cairo University
Responsible party
Hania wael (Master degree candidate, Cairo University) — Principal investigator
First posted
Jul 23, 2026
Start date
May 14, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Hania Haggag
Contact
hania.haggag@dentistry.cu.edu.eg
+01210239417

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion